LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) today saluted Gilead Sciences for its recent agreement to cut its AIDS drug prices to help address the severe crisis facing the nation’s AIDS Drug Assistance Program (ADAP), a network of federal and state funded programs that provide life-saving HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS nationwide. On Wednesday of this week, the ADAP Crisis Task Force (ACTF), announced that it had, “…reached new terms with Gilead Sciences that extend additional voluntary discounts and rebates for most Gilead products purchased by state AIDS Drug Assistance Programs (ADAPs).”
